ES2158859T3 - Estereoisomeros itraconazol y saperconazol. - Google Patents

Estereoisomeros itraconazol y saperconazol.

Info

Publication number
ES2158859T3
ES2158859T3 ES93905338T ES93905338T ES2158859T3 ES 2158859 T3 ES2158859 T3 ES 2158859T3 ES 93905338 T ES93905338 T ES 93905338T ES 93905338 T ES93905338 T ES 93905338T ES 2158859 T3 ES2158859 T3 ES 2158859T3
Authority
ES
Spain
Prior art keywords
saperconazol
itraconazol
stereoisomeros
preparation
complexes
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES93905338T
Other languages
English (en)
Inventor
Jan Heeres
Jean-Louis Mesens
Jozef Peeters
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Janssen Pharmaceutica NV
Original Assignee
Janssen Pharmaceutica NV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=25316567&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES2158859(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Janssen Pharmaceutica NV filed Critical Janssen Pharmaceutica NV
Application granted granted Critical
Publication of ES2158859T3 publication Critical patent/ES2158859T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y15/00—Nanotechnology for interacting, sensing or actuating, e.g. quantum dots as markers in protein assays or molecular motors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nanotechnology (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Communicable Diseases (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

LA PRESENTE INVENCION SE REFIERE A LAS FORMAS ESTEREOISOMERICAS DE ITRACONAZOL (X = CL) Y SAPERCONAZOL (X = F), QUE SE PUEDEN REPRESENTAR CON LA FORMULA (CIS-(I)) Y A LAS SALES DE ADICION ACIDAS FARMACEUTICAMENTE ACEPTABLES DE LAS MISMAS, A LOS PROCESOS PARA LA PREPARACION DE DICHAS FORMAS ESTEREOISOMERICAS, A LOS COMPLEJOS DE LAS MISMAS CON DERIVADOS DE CICLODEXTRINAS, A LAS COMPOSICIONES FARMACEUTICAS QUE CONTIENE DICHOS COMPLEJOS Y A LOS METODOS PARA LA PREPARACION DE DICHOS COMPLEJOS Y COMPOSICIONES FARMACEUTICAS.
ES93905338T 1992-03-18 1993-03-10 Estereoisomeros itraconazol y saperconazol. Expired - Lifetime ES2158859T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US85364892A 1992-03-18 1992-03-18

Publications (1)

Publication Number Publication Date
ES2158859T3 true ES2158859T3 (es) 2001-09-16

Family

ID=25316567

Family Applications (1)

Application Number Title Priority Date Filing Date
ES93905338T Expired - Lifetime ES2158859T3 (es) 1992-03-18 1993-03-10 Estereoisomeros itraconazol y saperconazol.

Country Status (21)

Country Link
US (1) US5998413A (es)
EP (1) EP0631578B1 (es)
KR (1) KR100243534B1 (es)
AT (1) ATE201408T1 (es)
AU (1) AU665988B2 (es)
CA (1) CA2117651C (es)
CZ (1) CZ286619B6 (es)
DE (1) DE69330248T2 (es)
DK (1) DK0631578T3 (es)
ES (1) ES2158859T3 (es)
FI (1) FI113175B (es)
GR (1) GR3036368T3 (es)
HU (1) HU221189B1 (es)
NO (1) NO307786B1 (es)
NZ (1) NZ249494A (es)
PL (1) PL172358B1 (es)
PT (1) PT631578E (es)
RU (1) RU2127733C1 (es)
SK (1) SK283118B6 (es)
WO (1) WO1993019061A1 (es)
ZA (1) ZA931906B (es)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH08509464A (ja) * 1993-01-27 1996-10-08 セプラコア，インコーポレイテッド （２ｒ，４ｓ）イトラコナゾールを使用する方法および組成物
PH31594A (en) * 1993-09-30 1998-11-03 Janssen Pharmaceutica Nv Oral formulations on an antifungal.
TW438601B (en) * 1994-05-18 2001-06-07 Janssen Pharmaceutica Nv New mucoadhesive emulsion compositions and a process for the preparation thereof
US5486625A (en) * 1994-07-08 1996-01-23 Schering Corporation Process for the preparation of chiral intermediates useful for the synthesis of antifungal agents
ES2112151B1 (es) * 1995-03-17 1999-09-16 Menarini Lab Nuevos compuestos homoquirales para la preparacion de ketoconazol, terconazol y antifungicos relacionados, procedimiento para su fabricacion y utilizacion de los mismos.
DE69733664T3 (de) 1996-04-19 2011-04-14 Grifols Inc. (n.d. Ges.d.Staates Delaware), Los Angeles Verfahren zur INaktivierung von Viren und Lyophilisierung von Blutproteinen
ATE255883T1 (de) * 1996-05-20 2003-12-15 Janssen Pharmaceutica Nv Fungizide mittel mit verbesserter bioverfügbarkeit
EP0942725A1 (en) * 1996-11-12 1999-09-22 Sepracor, Inc. Use of cis-hydroxyitraconazole in order to avoid side-effects of itraconazole and hydroxyintraconazole
JP2001504121A (ja) * 1996-11-12 2001-03-27 セプラコール，インク． ２ｒ，４ｓ，ｒ，ｓ―および２ｓ，４ｒ，ｒ，ｓ―ヒドロキシイトラコナゾール―およびヒドロキシサパーコナゾール誘導体
CN1237174A (zh) * 1996-11-12 1999-12-01 塞普拉科公司 2r,4s,s,r－和2s,4r,s,r－羟基伊曲康唑
WO1998021204A1 (en) 1996-11-12 1998-05-22 Sepracor, Inc. 2r,4s,s,s- and 2s,4r,s,s-hydroxyitraconazole
AU5251398A (en) * 1996-11-12 1998-06-03 Sepracor, Inc. (2r,4s,r,r-) and (2s,4r,r,r-)hydroxyitraconazole
WO1998034934A1 (en) 1997-02-11 1998-08-13 Janssen Pharmaceutica N.V. Amino acid ester containing azole antifungals
US6683100B2 (en) 1999-01-19 2004-01-27 Novartis Ag Organic compounds
US6194181B1 (en) 1998-02-19 2001-02-27 Novartis Ag Fermentative preparation process for and crystal forms of cytostatics
EP0957101A1 (en) * 1998-05-14 1999-11-17 Janssen Pharmaceutica N.V. Water soluble azoles as broad-spectrum antifungals
ES2251985T3 (es) 1999-03-24 2006-05-16 R.P. Scherer Technologies, Inc. Particula granulada para mejorar la solubilidad acuosa de farmacos, y su procedimiento de preparacion.
KR100331529B1 (ko) * 1999-06-16 2002-04-06 민경윤 난용성 항진균제의 경구투여용 조성물 및 그의 제조 방법
US6932861B2 (en) 2000-11-28 2005-08-23 Fmc Corporation Edible PGA coating composition
KR100438485B1 (ko) * 2001-08-13 2004-07-09 한국디디에스제약 주식회사 아졸류 항진균제의 약제학적 조성물
US7790905B2 (en) 2002-02-15 2010-09-07 Mcneil-Ppc, Inc. Pharmaceutical propylene glycol solvate compositions
US7927613B2 (en) 2002-02-15 2011-04-19 University Of South Florida Pharmaceutical co-crystal compositions
US7446107B2 (en) * 2002-02-15 2008-11-04 Transform Pharmaceuticals, Inc. Crystalline forms of conazoles and methods of making and using the same
WO2004000284A1 (en) 2002-06-21 2003-12-31 Transform Pharmaceuticals, Inc. Pharmaceutical compositions with improved dissolution
CA2477923C (en) 2002-03-01 2021-02-23 University Of South Florida Multiple-component solid phases containing at least one active pharmaceutical ingredient
EP1511490A4 (en) * 2002-05-31 2009-03-11 Transform Pharmaceuticals Inc NOVEL CONAZOLE CRYSTALLINE FORMS AND RELATED METHODS, PHARMACEUTICAL COMPOSITIONS AND METHODS
US20070059356A1 (en) * 2002-05-31 2007-03-15 Almarsson Oern Pharmaceutical co-crystal compositions of drugs such as carbamazepine, celecoxib, olanzapine, itraconazole, topiramate, modafinil, 5-fluorouracil, hydrochlorothiazide, acetaminophen, aspirin, flurbiprofen, phenytoin and ibuprofen
KR100446256B1 (ko) * 2002-07-11 2004-09-01 경동제약 주식회사 고 광학선택성을 가지는시스-2-(브로모메틸)-2-(2,4-디클로로페닐)-13-디옥소란-4-메틸알콜의 제조방법
US8183290B2 (en) 2002-12-30 2012-05-22 Mcneil-Ppc, Inc. Pharmaceutically acceptable propylene glycol solvate of naproxen
US8486456B2 (en) 2005-08-08 2013-07-16 Abbott Gmbh & Co., Kg Itraconazole compositions with improved bioavailability
PL1912626T3 (pl) 2005-08-08 2016-10-31 Postaci użytkowe o polepszonej biodostępności
US8653083B2 (en) 2005-08-22 2014-02-18 The Johns Hopkins University Hedgehog pathway antagonists to treat disease
EP2753179A4 (en) * 2011-09-09 2015-03-04 Univ Leland Stanford Junior TOPICAL ITRACONAZOLE FORMULATIONS AND THEIR USE
CN102379844A (zh) * 2011-10-31 2012-03-21 广州维美投资有限公司 一种伊曲康唑异构体注射剂
CN105061411A (zh) * 2015-06-23 2015-11-18 扬州艾迪生物科技有限公司 一种光学异构体2s,4r,2’s-伊曲康唑晶型及制备方法与应用
CN106146480B (zh) * 2016-07-18 2019-08-06 山东罗欣药业集团恒欣药业有限公司 一种伊曲康唑的制备方法

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4267179A (en) * 1978-06-23 1981-05-12 Janssen Pharmaceutica, N.V. Heterocyclic derivatives of (4-phenylpiperazin-1-yl-aryloxymethyl-1,3-dioxolan-2-yl)methyl-1H-imidazoles and 1H-1,2,4-triazoles
US4287195A (en) * 1978-07-14 1981-09-01 Janssen Pharmaceutica, N.V. Heterocyclic derivatives of [4-(piperazin-1-yl-phenyloxymethyl)-1,3-dioxolan-2-ylmethyl]-1H-imidazoles and 1H-1,2,4-triazoles
US4490530A (en) * 1981-01-14 1984-12-25 Janssen Pharmaceutica N.V. Heterocyclic derivatives of (4-phenylpiperazin-1-yl-aryloxymethyl-1,3-dioxolan-2-yl)-methyl-1H-imidazoles and 1H-1,2,4-triazoles
HU191101B (en) * 1983-02-14 1987-01-28 Chinoin Gyogyszer Es Vegyeszeti Termekek Gyara Rt,Hu Process for preparing water-soluble cyclodextrin polymers substituted with ionic groups
DE3346123A1 (de) * 1983-12-21 1985-06-27 Janssen Pharmaceutica, N.V., Beerse Pharmazeutische praeparate von in wasser schwerloeslichen oder instabilen arzneistoffen und verfahren zu ihrer herstellung
GB8506792D0 (en) * 1985-03-15 1985-04-17 Janssen Pharmaceutica Nv Derivatives of y-cyclodextrin
US4916134A (en) * 1987-03-25 1990-04-10 Janssen Pharmacuetica N.V. 4-[4-[4-[4-[[2-(2,4-difluorophenyl)-2-(1H-azolylmethyl)-1,3-dioxolan-4-yl]me]phenyl]-1-piperazinyl]phenyl]triazolones
FR2622198B1 (fr) * 1987-10-21 1992-04-30 Mero Rousselot Satia Compositions granulees de polysaccharides a dissolution aqueuse instantanee, procede pour leur preparation et utilisation
US5002935A (en) * 1987-12-30 1991-03-26 University Of Florida Improvements in redox systems for brain-targeted drug delivery
US5017566A (en) * 1987-12-30 1991-05-21 University Of Florida Redox systems for brain-targeted drug delivery
HK1009335A1 (en) * 1989-04-03 1999-05-28 Janssen Pharmaceutica N.V. Regioselective substitutions in cyclodextrins
GB8908250D0 (en) * 1989-04-12 1989-05-24 Fisons Plc Formulations
US5214046A (en) * 1989-07-27 1993-05-25 Hoffmann-La Roche Inc. Substituted aminoalkoxybenzene anti-fungicidal compositions and use
JPH08509464A (ja) * 1993-01-27 1996-10-08 セプラコア，インコーポレイテッド （２ｒ，４ｓ）イトラコナゾールを使用する方法および組成物

Also Published As

Publication number Publication date
PL172358B1 (en) 1997-09-30
WO1993019061A1 (en) 1993-09-30
DE69330248T2 (de) 2002-03-21
NO943450D0 (no) 1994-09-16
SK110694A3 (en) 1995-04-12
HUT71835A (en) 1996-02-28
RU94045798A (ru) 1996-07-20
HK1010729A1 (en) 1999-06-25
NO943450L (no) 1994-11-11
GR3036368T3 (en) 2001-11-30
KR950700904A (ko) 1995-02-20
KR100243534B1 (ko) 2000-03-02
CZ286619B6 (cs) 2000-05-17
NZ249494A (en) 1996-04-26
HU221189B1 (en) 2002-08-28
FI944311A0 (fi) 1994-09-16
US5998413A (en) 1999-12-07
HU9402656D0 (en) 1994-11-28
CA2117651A1 (en) 1993-09-30
FI113175B (fi) 2004-03-15
NO307786B1 (no) 2000-05-29
ZA931906B (en) 1994-09-17
CZ221594A3 (en) 1995-01-18
DE69330248D1 (de) 2001-06-28
CA2117651C (en) 2006-01-03
PT631578E (pt) 2001-11-30
RU2127733C1 (ru) 1999-03-20
AU3632493A (en) 1993-10-21
DK0631578T3 (da) 2001-08-27
FI944311L (fi) 1994-09-16
SK283118B6 (sk) 2003-02-04
AU665988B2 (en) 1996-01-25
EP0631578A1 (en) 1995-01-04
ATE201408T1 (de) 2001-06-15
EP0631578B1 (en) 2001-05-23

Similar Documents

Publication Publication Date Title
ES2158859T3 (es) Estereoisomeros itraconazol y saperconazol.
ES2071621T3 (es) Enantiomero dextrogiro del alfa-(tetrahidro-4,5,6,7-tieno-(3,2-c)-piridil-5)(cloro-2-fenil) acetato de metilo, su procedimiento de preparacion y las composiciones farmaceuticas que lo contienen.
ES2081187T3 (es) Nuevas naftil-alquil-aminas, su procedimiento de preparacion y composiciones farmaceuticas que las contienen.
MX9300498A (es) Derivados de n-sulfonil-2-oxo-indol, procedimiento para su preparacion y composiciones farmaceuticas que los contienen.
MX173630B (es) Derivados de aminoacido, procedimiento para su preparacion y su preparacion y medicamento que los contiene
ES2055860T3 (es) Derivados 2-aminopirimidinona.
ES8500276A1 (es) Procedimiento para preparar n2-acil-9-(1,3-dihidroxi-2-propoximetil)-guaninas y sus sales famaceuticamente aceptables.
SV1994000028A (es) Nuevas sulfonilamino pirimidinas, ref. 10916 sv.
DE69110625D1 (de) Oxazolopyridinderivate, Verfahren zu ihrer Herstellung und die sie enthaltenden pharmazeutischen Zusammensetzungen.
ES2123039T3 (es) Nuevas 3-(hidroxi-bencilidenil)-indolin-2-onas, su procedimiento de preparacion y composiciones farmaceuticas que las contienen.
MX9503529A (es) Derivados de glicinamida, procedimiento para su preparacion y medicamentos que los contienen.
ES2118203T3 (es) Nuevos derivados benzopiranicos, su procedimiento de preparacion y composiciones farmaceuticas que los contienen.
MX9207494A (es) 4(5)-amino-1,8-naftiridinas substituidas, procedimiento para su preparacion y composiciones farmaceuticas que las contienen.
SE8400332D0 (sv) Forening for anvendning som mellanprodukt vid framstellning av lekemedel
MX9300399A (es) Derivados heterotriciclicos.
ES2105285T3 (es) Nuevos derivados de la adenosina, sus procedimientos de preparacion, composiciones farmaceuticas que los contienen.
ES2103440T3 (es) Nuevas amidas y sulfonamidas naftalenicas, procedimiento de preparacion y composiciones farmaceuticas que las contienen.
ES2012736A6 (es) Procedimiento para la preparacion de derivados triciclicos de 3-oxopropanonitrilo.
ES2125963T3 (es) Nuevos derivados espiranicos del 3-amino-cromano, sus procedimientos de preparacion y las composiciones farmaceuticas que los contienen.
ES2153457T3 (es) Amino-alquil-benzoxazolinonas y benzotiazolinonas, su procedimiento de preparacion y las composiciones farmaceuticas que las contienen.
ES2172023T3 (es) Nuevos derivados tetrahidro-piridinicos sustituidos, su procedimiento de preparacion y las composiciones farmaceuticas que los contienen.
ES2077473T3 (es) Nuevos compuestos tiocromanicos, su procedimiento de preparacion y composiciones farmaceuticas que los contienen.
ES2130548T3 (es) Nuevos derivados alquil-amino-indanos, su procedimiento de preparacion y las composiciones farmaceuticas que los contienen.
MX9203234A (es) Derivados de 5-halovinil-2-desoxiuridina y composiciones farmaceuticas que los contienen.
FR2430230A1 (fr) Medicaments a base de derives de l'acide anthranilique

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 631578

Country of ref document: ES